SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment

• DOI: 10.1186/s12877-018-0782-7
• Publication Date: 2018-04-16T12:24:35Z
• Authors: Manuel Montero-Od...; Quincy J. Almeida; Amer M. Burhan; Richard Camicioli; Julien Doyon; Sarah Fraser; Karen Li; Teresa Liu-Ambrose; Laura Middleton; Susan Muir-Hunter; William McIlroy; José A. Morais; Frederico Pierucc...; Kevin Shoemaker; Mark Speechley; Akshya Vasudev; G. Y. Zou; Nicolas Berryman; Maxime Lussier; Leanne Vanderhaeghe; Louis Bherer
• Keywords: Cognitive Training; Aerobic Exercise

Physical exercise, cognitive training, and vitamin D are low cost interventions that have the potential to enhance function mobility in older adults, especially pre-dementia states such as Mild Cognitive Impairment (MCI). Aerobic progressive resistance exercises benefits performance, though evidence is somewhat inconsistent. We postulate combined aerobic exercise (AE) training (RT) (combined exercise) will a better effect on cognition than balance toning control (BAT) intervention adults with MCI. also expect adding supplementation multimodal intervention, synergistic efficacy. The SYNERGIC trial (SYNchronizing Exercises, Remedies GaIt Cognition) multi-site, double-blinded, five-arm, controlled assesses synergic of AE RT mobility, without Two-hundred participants MCI aged 60 85 years old be randomized one five arms, four which include plus combinations dual-task (real vs. sham) (3 × 10,000 IU/wk. placebo) quasi-factorial design, arm receives all interventions. primary outcome measure ADAS-Cog (13 modalities) measured at baseline 6 months follow-up. Secondary outcomes neuroimaging, neuro-cognitive gait serum biomarkers inflammation (C reactive protein interleukin 6), neuroplasticity (brain-derived neurotropic factor), endothelial markers (vascular growth factor 1), levels. Trial establish efficacy feasibility improve performance These may contribute new approaches stabilize reverse cognitive-mobility decline individuals Identifier: NCT02808676. https://www.clinicaltrials.gov/ct2/show/NCT02808676 .